The class of GIPC inhibitors comprises a diverse array of chemical compounds that exert their effects either directly on GIPC or indirectly by influencing key signaling pathways and cellular processes associated with GIPC functionality. These inhibitors have the potential to modulate GIPC-related functions and cellular responses through their specific interactions with well-defined biochemical and cellular pathways. One prominent group of GIPC inhibitors includes compounds that target the PI3K/AKT pathway, such as Rapamycin, Wortmannin, and LY294002. These inhibitors disrupt the intricate signaling cascade of PI3K/AKT, leading to downstream alterations that may impact GIPC-mediated cellular processes. By interfering with this pathway, these compounds showcase the interconnectedness of intracellular signaling networks and GIPC functionality. Additionally, GIPC inhibitors like PD98059, U0126, and Trametinib operate through the MAPK/ERK pathway, disrupting signaling cascades that intersect with GIPC-related processes. The intricate modulation of the MAPK/ERK pathway by these inhibitors highlights the potential for indirect regulation of GIPC and the complexity of cellular responses influenced by GIPC.
Stress-related pathways are also targeted by GIPC inhibitors such as SB203580, JNK Inhibitor VIII, and SP600125. These compounds showcase the interplay between stress signaling and GIPC-mediated functions, emphasizing the diverse cellular responses modulated by GIPC in response to stress. Furthermore, GIPC inhibitors like SB431542 and TPCA-1 act on TGF-β and NF-κB pathways, respectively. The indirect modulation of GIPC through these pathways underscores the intricate regulatory networks that influence GIPC-mediated cellular processes, including those related to TGF-β signaling and NF-κB-mediated responses. In summary, the class of GIPC inhibitors demonstrates the complexity of cellular regulation by targeting specific pathways. These inhibitors, whether direct or indirect, offer valuable insights into the intricate web of signaling cascades that intersect with GIPC functionality.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, disrupts the PI3K/AKT/mTOR pathway. It indirectly affects GIPC by modulating downstream signaling, altering cellular processes and potentially inhibiting GIPC-mediated functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
As a PI3K inhibitor, Wortmannin disrupts the PI3K/AKT pathway. Its influence on this pathway can indirectly impact GIPC, potentially modulating its cellular functions and interactions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, targets the PI3K/AKT pathway. Its inhibition of PI3K can lead to indirect modulation of GIPC, affecting cellular processes associated with GIPC function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, influences stress-related pathways. Through its effect on stress signaling, it may indirectly modulate GIPC, altering cellular responses and potentially impacting GIPC-mediated functions. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, disrupts TGF-β signaling. Its indirect influence on GIPC may occur through modulation of TGF-β-related pathways, affecting cellular processes associated with GIPC function. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $267.00 | 2 | |
JNK Inhibitor VIII inhibits the JNK pathway. By disrupting this stress-related pathway, it may indirectly modulate GIPC, influencing cellular responses and potentially impacting GIPC-mediated functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, affects stress-related signaling pathways. Its impact on stress responses can indirectly influence GIPC, potentially modulating cellular processes associated with GIPC function. | ||||||
Bemcentinib | 1037624-75-1 | sc-507363 | 10 mg | $900.00 | ||
R428, a focal adhesion kinase (FAK) inhibitor, targets FAK signaling. Its inhibition of FAK can indirectly impact GIPC, potentially modulating cellular processes associated with GIPC function and FAK signaling. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, a MEK inhibitor, disrupts the MAPK/ERK pathway. Its influence on this pathway can indirectly affect GIPC, leading to alterations in downstream signaling and potential modulation of GIPC-mediated cellular functions. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $130.00 | 12 | |
TPCA-1, an IKK-2 inhibitor, targets the NF-κB pathway. Through its impact on NF-κB signaling, it may indirectly modulate GIPC, affecting cellular processes associated with GIPC function and NF-κB-mediated responses. |